Search 

Senior Consultant at Nicholas Hall Consultancy. I am the Head the M&A and Licensing department as well as manage strategic consultancy projects (e.g. market entry, product launches, pricing, etc). I, along with my team have helped global pharma companies and private equity firms find suitable acquisition and licensing opportunities. Let's meet to discuss how Nicholas Hall Consultancy can help you. 

Present Value specialise in acquisition, divestment, licensing, partnering and strategy in life science. Our experience is purely pharmaceutical and anyone who works on your prospective project will have worked in the industry for some time.  Of course, we also benefit hugely from an excellent network that has been built organically through our project work (a recent project may saw us liaising with more than one hundred companies across Europe as an example).

Recently celebrating over 10 years of success for our clients, Present Value was founded back in 2007. You can get a flavour of the types of projects and transactions we work on by looking at some of the cases histories on our website.  Alternatively, please see below for a synopsis...

1. Acquire - We will find you new targets:

·         It is difficult to find businesses or assets to acquire, especially the right shape and size for your business. We have a structured way of hunting for deals and maintain a database of potential sellers. We can be your extra set of eyes and ears out there.

2. Divest - You deserve the right value for your asset or company:

·         We would not call a company Present Value if we did not understand the equation. It is not just about an equation, it is about a thorough understanding of what drives the value in your business. We have developed an efficient process to gain you best value for your asset. You get on with running your business while we organise all the relevant documentation and deal with potential buyers.

3. Licensing - Take the essential route to pharmaceutical licensing:

·         We spend a lot of time at the pharmaceutical industry’s partnering meetings and have a good idea of what each company is looking for or what they might be offering. We tend to stick to branded innovative licensing.

4. Consulting - Expert analysis on every aspect in business of Life Science:

·         If you are struggling with something or looking to get some fresh ideas, we work on all sorts of business development projects and strategies. They are always about unlocking extra value and getting the best out of your assets.

All our projects are bespoke to you and should your project require more specialist corporate finance, regulatory or legal input we can cover that too and tend to put together a bespoke team of competent individuals or complimentary firms.

Our past and current clients range from individual entrepreneurs, family firms, country subsidiaries and global entities.  We are proud of our track record of repeat and continuing business from a number of our clients, many of whom have taken us with them when they move to a new company.

If you would like to have a chat about how we can help, please call on +44 (0) 1892 825663 or if you at any PLG, EMIG, Bio Europe event, we’re likely to be there too.

We’re generally useful to know and we look forward to hearing from you.

Both Andrew Dean and Adam Minshall are available for meetings in Montreux.  Alternatively, why not just find either of us for an informal chat.

Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, we pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, we are focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas we aim to develop drugs whose profile suggests they will be best in class, if not first in class

Specialties: Business Development, Licensing and Market Research support, Alliance Management and Customer Relations to the Biotech, Medtech, Pharmaceutical and Life Sciences Industries, and Start-Up Coaching.

www.linkedin.com/in/simon-bennett-0390796

1.  Looking for co-investment opportunities under TPI's i2020 Accelerator scheme: early-stage, seed round, small molecule focus

2.  Looking for assets for licensing for clients, including: rare disease assets (except cell & gene therapy), CVD, pain management, respiratory, innovative technologies, 505(b)(2) products

3.  Meeting companies interested in state-of-the -art machine learning solutions for drug discovery

4.  Meeting companies interested in acquiring antibody libraries

5.  Meeting companies interested in acquiring a phase II ready asset in multiple myeloma

6.  Meeting companies interested in a range of market-ready nickel allergy products

Silence Therapeutics is a leading RNAi company, developing highly innovative medicines with life-saving potential for patients with serious and rare diseases, based upon its proprietary technology platform in GalNAc conjugated siRNA.

The Company is in a strong position to maximise the potential of its IP and technology through collaborations and the advancement of internal programmes toward the clinic. Silence’s lead candidate SLN124 will move into clinical development in the coming year.